MGC50722 Blocking Peptide
- Known as:
- MGC50722 Blocking Peptide
- Catalog number:
- 33r-2110
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Fitzgerald industries international
- Gene target:
- MGC50722 Blocking Peptide
Related genes to: MGC50722 Blocking Peptide
- Gene:
- CCDC187 NIH gene
- Name:
- coiled-coil domain containing 187
- Previous symbol:
- -
- Synonyms:
- MGC50722
- Chromosome:
- 9q34.3
- Locus Type:
- gene with protein product
- Date approved:
- 2015-09-17
- Date modifiied:
- 2015-09-17
Related products to: MGC50722 Blocking Peptide
Related articles to: MGC50722 Blocking Peptide
- Considering the lack of molecular background of the metastatic process in pancreatic ductal adenocarcinoma (PDAC) and the fact that the location of the metastasis may carry prognostic information and potential therapeutic opportunities, we aimed to explore genomic profiles of metastases from diverse loci and their value for the patients' therapeutic management. DNA samples from paired primary and metastatic tissue of 20 patients were microdissected and sequenced using whole exome target enrichment. Somatic genetic variability, copy number variations (CNVs), and mutational signatures were assessed for associations with clinical data of patients. KRAS (78% in primary tumors, 74% in metastases), TP53 (67%-68%), CDKN2A (28%-37%), and SMAD4 (22%-26%) were the most commonly mutated oncodrivers in primary tumors and metastases. Other frequently mutated genes were CCDC187 (50%-58%), MUC5AC (50%-53%), EPPK1 (39%-63%), SYN2 (39%-26%), MUC19 (33%-47%), MUC3A (33%-26%), DNAH12 (28%-37%), ZBED3 (22%-26%), PKHD1L1 (28%-16%), and GTPBP6 (11%-32%). Lung metastases differed from other metastatic sites (liver, stomach, and locoregional) in a higher frequency of nonsense mutations in the MH2 domain of SMAD4, oncodriver comutations, gains on chromosomes 2 and 20, CNV counts, and share of signature SBS5. Somatic alterations of KRAS in metastases (P = .041) and MUC3A in both loci (P = .041 and P = .011, respectively) and CNVs count and size in metastases (P = .024 and P = .011) associated with response to systemic chemotherapy. Patients with mutated KRAS (P = .045), high mutational load (P = .004), and frequent CNVs (P = .004) in metastatic loci had shortened survival after metastasis resection. Interestingly, the personalized treatment targetable alterations, such as microsatellite instability and mismatch repair or homologous recombination deficiencies did not differ between the primary tumors and paired metastases or between the metastases from different secondary sites and had no prognostic value. The results suggest a potential prognostic role of KRAS mutations, mutation load, and CNVs in PDAC patients after metastasectomy and encourage further molecular profiling for personalized treatment of PDAC patients with different metastasis localization. - Source: PubMed
Publication date: 2025/06/20
Loveček MartinStrouhal OndřejČervenková LenkaŠůsová SimonaHlaváč ViktorChottova Dvorakova MagdalenaHolý PetrLiška VáclavSkalický PavelSkanderová DanielaLanger AlešMohelníková-Duchoňová BeatriceSouček Pavel - The key evolutionary step leading to the pandemic virus was the acquisition of the PRRA furin cleavage motif at the spike glycoprotein S1/S2 junction by a progenitor of SARS-CoV-2. Two of its features draw attention: (i) it is absent in other known lineage B beta-coronaviruses, including the newly discovered coronaviruses in bats from Laos and Vietnam, which are the closest known relatives of the covid virus; and, (ii) it introduced the pair of arginine codons (CGG-CGG), whose usage is extremely rare in coronaviruses. With an occurrence rate of only 3%, the arginine CGG codon is considered a minority in SARS CoV-2. On the other hand, Laos and Vietnam bat coronaviruses contain receptor-binding domains that are almost identical to that of SARS-CoV-2 and can therefore infect human cells despite the absence of the furin cleavage motif. - Source: PubMed
Publication date: 2023/11/21
Romeu Antonio R - is an herbal medicine with anti-cancer effects. However, little is known about the anti-cancer effect of on colorectal cancer. Therefore, our study aimed to investigate the specific molecular mechanism of inhibition of colorectal cancer. - Source: PubMed
Publication date: 2023/03/20
Huang LingyuZou TongxiangLiang WenkenMo ChuneWei JianfenDeng YechengOu Minglin - Male infertility is a multifaceted disorder affecting approximately 50% of male partners in infertile couples. Over the years, male infertility has been diagnosed mainly through semen analysis, hormone evaluations, medical records and physical examinations, which of course are fundamental, but yet inefficient, because 30% of male infertility cases remain idiopathic. This dilemmatic status of the unknown needs to be addressed with more sophisticated and result-driven technologies and/or techniques. Genetic alterations have been linked with male infertility, thereby unveiling the practicality of investigating this disorder from the "omics" perspective. Omics aims at analyzing the structure and functions of a whole constituent of a given biological function at different levels, including the molecular gene level (genomics), transcript level (transcriptomics), protein level (proteomics) and metabolites level (metabolomics). In the current study, an overview of the four branches of omics and their roles in male infertility are briefly discussed; the potential usefulness of assessing transcriptomic data to understand this pathology is also elucidated. After assessing the publicly obtainable transcriptomic data for datasets on male infertility, a total of 1385 datasets were retrieved, of which 10 datasets met the inclusion criteria and were used for further analysis. These datasets were classified into groups according to the disease or cause of male infertility. The groups include non-obstructive azoospermia (NOA), obstructive azoospermia (OA), non-obstructive and obstructive azoospermia (NOA and OA), spermatogenic dysfunction, sperm dysfunction, and Y chromosome microdeletion. Findings revealed that 8 genes () were commonly differentially expressed between all disease groups. Likewise, 56 genes were common between NOA versus NOA and OA (). These genes, particularly the above-mentioned 8 genes, are involved in diverse biological processes such as germ cell development, spermatid development, spermatid differentiation, regulation of proteolysis, spermatogenesis and metabolic processes. Owing to the stage-specific expression of these genes, any mal-expression can ultimately lead to male infertility. Therefore, currently available data on all branches of omics relating to male fertility can be used to identify biomarkers for diagnosing male infertility, which can potentially help in unravelling some idiopathic cases. - Source: PubMed
Publication date: 2022/02/14
Omolaoye Temidayo SOmolaoye Victor AKandasamy Richard KHachim Mahmood YaseenDu Plessis Stefan S